Roger Hawley Purchases 140,000 Shares of Dare Bioscience Inc (DARE) Stock

Dare Bioscience Inc (NASDAQ:DARE) Director Roger Hawley acquired 140,000 shares of Dare Bioscience stock in a transaction on Monday, June 11th. The stock was purchased at an average price of $1.45 per share, with a total value of $203,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Dare Bioscience opened at $1.31 on Thursday, Marketbeat.com reports. Dare Bioscience Inc has a 12 month low of $0.74 and a 12 month high of $12.40. The company has a market cap of $16.91 million, a PE ratio of -1.06 and a beta of 2.74.

Dare Bioscience (NASDAQ:DARE) last released its quarterly earnings results on Monday, April 2nd. The biotechnology company reported ($0.49) EPS for the quarter. research analysts forecast that Dare Bioscience Inc will post -1.26 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Dare Bioscience stock. CVI Holdings LLC purchased a new position in shares of Dare Bioscience Inc (NASDAQ:DARE) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 471,661 shares of the biotechnology company’s stock, valued at approximately $395,000. Dare Bioscience comprises 0.5% of CVI Holdings LLC’s investment portfolio, making the stock its 22nd biggest holding. CVI Holdings LLC owned about 4.13% of Dare Bioscience at the end of the most recent quarter. Hedge funds and other institutional investors own 9.04% of the company’s stock.

A number of brokerages have weighed in on DARE. Roth Capital began coverage on Dare Bioscience in a research note on Wednesday, May 16th. They issued a “buy” rating and a $6.00 price objective for the company. ValuEngine upgraded Dare Bioscience from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

About Dare Bioscience

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit